Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6408 posts found.

FDA narrows use of J&J vaccine due to blood clot risk

May 6, 2022 Medical Communications

The FDA has limited the use of Johnson & Johnson’s coronavirus vaccine, to adults who cannot, or refuse to get, …
News

AstraZeneca’s heart disease drug meets key endpoints in Phase III

May 6, 2022 Medical Communications

AstraZeneca’s treatment for heart disease has delivered positive high-level results from its Phase III DELIVER trial.Farxiga (dapagliflozin) is already approved …
News

Discharging untested patients to care homes was ‘unlawful’, says high court ruling

April 29, 2022 Medical Communications

The High Court has ruled that government policies on discharging untested patients from hospital to care homes in England, at …
News

Pfizer DMD trial moves forward after FDA lifts hold

April 29, 2022 Medical Communications

Pfizer has announced that it will open the first ever US sites in its Phase III trial study, evaluating its …
News

FDA approval for first drug to treat inherited heart condition

April 29, 2022 Medical Communications

Bristol Myers Squibb has received approval from the FDA for their drug, Camzyos™ (mavacamten), marking the drug as the first …
News

Beijing enforces mass COVID-19 testing and closes neighbourhoods

April 26, 2022 Medical Communications

Beijing is enforcing mass testing and closing down access to neighbourhoods as it seeks to contain a new COVID-19 outbreak. …
News

Mundipharma and Cidara Therapeutics report positive Phase III results into candidemia treatment

April 26, 2022 Medical Communications

Mundipharma and Cidara Therapeutics have presented data from the Phase III ReSTORE trial of rezafungin, in the treatment of candidemia …
News

Vivesto signs agreement with CRO to evaluate anti-cancer drug formulations

April 22, 2022 Medical Communications

Vivesto AB, an oncology-focused pharmaceutical company, has announced that it is advancing research into its proprietary drug delivery formulations, and …
News

Orasis Pharmaceuticals announces positive Phase III results of eye drop candidate

April 22, 2022 Medical Communications

Orasis Pharmaceuticals has announced that the Phase III NEAR-1 and NEAR-2 clinical trials, which evaluated the efficacy and safety of …
News

FDA approves Phase III Acute Respiratory Distress Syndrome (ARDS) Trial

April 22, 2022 Medical Communications

The FDA has approved Direct Biologics to proceed with its Phase III clinical trial into the treatment of Acute Respiratory …
News

WHO “strongly recommends” Paxlovid, calls for wide distribution from Pfizer

April 22, 2022 Medical Communications

WHO has endorsed the use of Pfizer’s oral antiviral treatment for high-risk patients with mild COVID-19, following an analysis of …
News

NICE publishes guidance for atopic dermatitis treatments

April 8, 2022 Medical Communications

Abrocitinib, upadacitinib, and tralokinumab are not recommended for treating moderate to severe atopic dermatitis. The recommendation does not affect patients …
News

First-of-its-kind vaccine manufacturing facility shipped to Africa

April 8, 2022 Medical Communications

KeyPlants announced the shipping a first-of-its-kind vaccine manufacturing filling facility to Senegal, in West Africa.
News

Acadia seeks first-ever FDA approval in Rett Syndrome

April 8, 2022 Medical Communications

Acadia has presented an update on its Phase III LAVENDER study of trofinetide for Rett Syndrome at the American Academy …
News

NIH funds tuberculosis research advancement centres

April 8, 2022 Medical Communications

News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026